Vanguard discloses 6.74% Xeris Biopharma (XERS) stake in Schedule 13G/A

Rhea-AI Filing Summary

The Vanguard Group has filed an amended Schedule 13G reporting beneficial ownership of Xeris Biopharma Holdings Inc common stock. Vanguard reports beneficial ownership of 11,186,677 shares, representing 6.74% of the outstanding common stock as of the triggering date.

Vanguard reports no sole voting or dispositive power, with shared voting power over 1,339,227 shares and shared dispositive power over 11,186,677 shares. The filing explains that Vanguard’s clients, including registered investment companies and other managed accounts, have the right to receive dividends and sale proceeds, and that no single client holds more than 5% of the class. Vanguard states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Xeris Biopharma. The filing also notes an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries may report beneficial ownership on a disaggregated basis.

Insights

Institutional Ownership Analyst

Vanguard discloses a 6.74% passive stake in Xeris Biopharma.

The filing shows The Vanguard Group beneficially owning 11,186,677 Xeris Biopharma common shares, or 6.74% of the class. Voting power is limited, with no sole voting authority and shared voting over 1,339,227 shares, indicating primarily custodial and index-related holdings.

Economic rights to dividends and sale proceeds belong to Vanguard’s clients, with no single client exceeding 5% of the class. Vanguard certifies the position is held in the ordinary course of business and not to influence control. An internal realignment effective January 12, 2026 means future ownership reports may be split among subsidiaries, which could change how institutional ownership appears in subsequent disclosures without necessarily changing aggregate exposure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/30/2026 - 02:43 PM Learn about SEC filing dates

FAQ

What percentage of Xeris Biopharma (XERS) does The Vanguard Group own?

The Vanguard Group reports beneficial ownership of 6.74% of Xeris Biopharma’s common stock, equal to 11,186,677 shares. This reflects institutional investment exposure held across Vanguard-managed funds and accounts, rather than a direct strategic stake by Vanguard itself.

How many Xeris Biopharma shares does Vanguard have voting and dispositive power over?

Vanguard reports no sole voting or dispositive power, with shared voting power over 1,339,227 shares and shared dispositive power over 11,186,677 shares. This structure is typical for a large asset manager acting on behalf of multiple client accounts and funds.

Is Vanguard’s stake in Xeris Biopharma intended to influence control of the company?

Vanguard certifies the Xeris Biopharma shares were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control. The position supports client investment strategies rather than an activist or control-seeking campaign.

Who ultimately benefits from Vanguard’s Xeris Biopharma holdings?

The filing states that Vanguard’s clients, including registered investment companies and other managed accounts, have the right to receive dividends and sale proceeds from the Xeris Biopharma shares. No single client’s interest exceeds 5% of the class.

What internal realignment did The Vanguard Group disclose in relation to its Xeris position?

Vanguard notes that on January 12, 2026 it underwent an internal realignment and no longer performs portfolio management or proxy voting. Certain subsidiaries or divisions are expected to report beneficial ownership separately, though they will pursue the same investment strategies.

What type of SEC filing did Vanguard submit for its Xeris Biopharma holdings?

The Vanguard Group submitted an amended Schedule 13G/A, which is used by institutional investors reporting passive beneficial ownership above 5% of a company’s registered equity securities. The filing relates to Xeris Biopharma’s common stock with CUSIP 98422E103.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Xeris Biopharma Holdings Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

98422E103

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 98422E103

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,339,227.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 11,186,677.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,186,677.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.74 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. As of that date, The Vanguard Group, Inc. no longer performs portfolio management services or administers proxy voting. In accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that currently have, or are deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Xeris Biopharma Holdings Inc
(b)	Address of issuer's principal executive offices: 180 North LaSalle Street, Suite 1800, Chicago, IL, 60601
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd., Malvern, PA 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 98422E103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 11186677
(b)	Percent of class: 6.74 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 1339227
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 11186677
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	01/30/2026